Patents Assigned to AbbVie Inc.
  • Publication number: 20210130346
    Abstract: Compounds of formula (I), wherein R1, R2, R3, R5, R6, R7, A1, A2, A3, A4, X1, and X2 have any of the values defined in the specification and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS are provided. Pharmaceutical compositions comprising of compounds of formula (I) are also provided.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 6, 2021
    Applicant: AbbVie Inc.
    Inventors: David Hardee, Jason Brewer, Lisa Hasvold, Dachun Liu, Keith McDaniel, Michael Schrimpf, George Sheppard
  • Patent number: 10993942
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 4, 2021
    Assignees: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Patent number: 10995095
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: May 4, 2021
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Patent number: 10981924
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: April 20, 2021
    Assignee: AbbVie Inc.
    Inventors: Jayanthy Jayanth, Ben Klünder, Mohamed-Eslam Mohamed, Ahmed A. Othman, Patrick J. Marroum, Peter T. Mayer
  • Patent number: 10981923
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: April 20, 2021
    Assignee: AbbVie Inc.
    Inventors: Ayman Allian, Thomas B. Borchardt, Jayanthy Jayanth, Patrick J. Marroum, Peter T. Mayer, Mathew M. Mulhern, Fredrik Lars Nordstrom, Ahmad Y. Sheikh
  • Patent number: 10954202
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: March 23, 2021
    Assignee: AbbVie Inc.
    Inventors: Zhaoming Xiong, Jennifer M. Frost, Philip R. Kym, Xueqing Wang, Shuang Chen, Dennie Welch
  • Publication number: 20210059968
    Abstract: The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.
    Type: Application
    Filed: April 21, 2020
    Publication date: March 4, 2021
    Applicant: AbbVie Inc.
    Inventors: Alexandru DEAC, Ye HUANG, John M. LIPARI, Alexander RUGGLES, Thin Yu TUN
  • Publication number: 20210061813
    Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: June 13, 2019
    Publication date: March 4, 2021
    Applicant: AbbVie Inc.
    Inventors: Neil WISHART, Maria A. ARGIRIADI, David J. CALDERWOOD, Anna M. ERICSSON, Bryan A. FIAMENGO, Kristine E. FRANK, Michael M. FRIEDMAN, Dawn M. GEORGE, Eric R. GOEDKEN, Nathan S. JOSEPHSOHN, Biqin C. LI, Michael J. MORYTKO, Kent D. STEWART, Jeffrey W. VOSS, Grier A. WALLACE, Lu WANG, Kevin R. WOLLER
  • Patent number: 10919961
    Abstract: The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: February 16, 2021
    Assignee: Abbvie, Inc.
    Inventor: Catherine Tripp
  • Publication number: 20210041337
    Abstract: Systems and methods for inspecting particles in a liquid beneficial agent are provided.
    Type: Application
    Filed: July 28, 2020
    Publication date: February 11, 2021
    Applicant: ABBVIE INC.
    Inventors: Edmund Matayoshi, Sheng Tu, Jie Wang
  • Patent number: 10913727
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 9, 2021
    Assignee: AbbVie Inc.
    Inventors: Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • Publication number: 20210030626
    Abstract: A pill dispenser includes a case body including a first compartment having a loading slot and a second compartment including a dispensing slot. The dispenser includes a cartridge configured to contain one or more pills and configured to align with the loading slot. The second compartment is adjacent to the first compartment. The dispenser further includes an actuator including a loading chamber. The actuator is joined to the case body proximate a first end of the case body and is rotatable about the case body from a loading position to a dispensing position. At the loading position, the loading chamber is aligned with the loading slot to receive a pill from the first compartment. At the dispensing position, the loading chamber is aligned with the dispensing slot to dispense the pill through the second compartment. A cap is removably coupled to a second end of the case body and is aligned with the second compartment and configured to receive the pill from the second compartment..
    Type: Application
    Filed: August 26, 2017
    Publication date: February 4, 2021
    Applicant: AbbVie Inc.
    Inventor: Bhimaprasad Medhal
  • Publication number: 20210023012
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first type of film-coated granules which comprise 50 mg of Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second type of film-coated granules which comprise 20 mg of Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: April 1, 2020
    Publication date: January 28, 2021
    Applicant: AbbVie Inc.
    Inventors: Wei Liu, Hoi Kei Lon, Sven Mensing, Jeffrey Schmidt, Neha Thakre, Thin Yu Tu
  • Publication number: 20210015938
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same.
    Type: Application
    Filed: July 31, 2020
    Publication date: January 21, 2021
    Applicant: AbbVie Inc.
    Inventors: Adrian D. Hobson, Michael J. McPherson, Wendy Waegell, Christian Goess, Axel Hernandez, Jr., Lu Wang, Lu Wang, Christopher C. Marvin, Ling C. Santora
  • Publication number: 20210009681
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Application
    Filed: February 7, 2020
    Publication date: January 14, 2021
    Applicant: AbbVie Inc.
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jije Gu, Susan Morgan-Lappe, Yingchun Li
  • Patent number: 10881659
    Abstract: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 5, 2021
    Assignee: ABBVIE INC.
    Inventors: Kristof Chwalisz, Laura A. Williams, Rita I. Jain, Janine D. North, Juki Wing-Keung Ng
  • Patent number: 10864249
    Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: December 15, 2020
    Assignees: MELINTA THERAPEUTICS, INC., ABBVIE INC.
    Inventors: Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James P. Petzel, Julie J. Pruyne, Douglas M. Reamer
  • Patent number: 10864196
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 15, 2020
    Assignees: Calico Life Sciences, LLC, AbbVie Inc.
    Inventors: Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • Patent number: 10857302
    Abstract: A syringe carrier for use within an automatic injection device includes a substantially tubular body having a first end, a middle portion, and a second end, configured to contain a portion of a syringe and displace the syringe within a housing of the automatic injection device from a first position to a second position; a first pair of legs defining at least a portion of a front opening in the substantially tubular body proximal to the first end; a second pair of legs defining at least a portion of a rear opening in the substantially tubular body proximal to the first end; and a syringe carrier coupler having a first beam and a second beam extending from the middle portion partially beyond the first pair of legs at the first end of the substantially tubular body.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: December 8, 2020
    Assignee: AbbVie Inc.
    Inventors: Sherwin S. Shang, Joseph F. Julian, Chuan Li, Eduard N. Tsvirko, Edwin Chim, Shubha Chethan Somashekar, Esra Ozdaryal
  • Patent number: 10851073
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: December 1, 2020
    Assignee: AbbVie Inc.
    Inventors: Geoff T. Halvorsen, Jennifer M. Frost, Philip R. Kym